RU2018125698A - Биоразлагаемые полукристаллические термопластичные мультиблочные сополимеры с разделенными фазами для контролируемого высвобождения биологически активных соединений - Google Patents
Биоразлагаемые полукристаллические термопластичные мультиблочные сополимеры с разделенными фазами для контролируемого высвобождения биологически активных соединений Download PDFInfo
- Publication number
- RU2018125698A RU2018125698A RU2018125698A RU2018125698A RU2018125698A RU 2018125698 A RU2018125698 A RU 2018125698A RU 2018125698 A RU2018125698 A RU 2018125698A RU 2018125698 A RU2018125698 A RU 2018125698A RU 2018125698 A RU2018125698 A RU 2018125698A
- Authority
- RU
- Russia
- Prior art keywords
- prepolymer
- biologically active
- mol
- composition according
- segment
- Prior art date
Links
- 229920001169 thermoplastic Polymers 0.000 title claims 12
- 239000004416 thermosoftening plastic Substances 0.000 title claims 12
- 150000001875 compounds Chemical class 0.000 title claims 11
- 238000013270 controlled release Methods 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 10
- 229920001577 copolymer Polymers 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- -1 D-lactide Chemical compound 0.000 claims 7
- 229920006030 multiblock copolymer Polymers 0.000 claims 7
- 229920001223 polyethylene glycol Polymers 0.000 claims 7
- 239000004970 Chain extender Substances 0.000 claims 6
- 239000004005 microsphere Substances 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 239000007943 implant Substances 0.000 claims 4
- 239000011859 microparticle Substances 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000005442 diisocyanate group Chemical group 0.000 claims 3
- 150000002009 diols Chemical class 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229920003169 water-soluble polymer Polymers 0.000 claims 3
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 239000003098 androgen Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 239000000262 estrogen Substances 0.000 claims 2
- 229940011871 estrogen Drugs 0.000 claims 2
- 239000000835 fiber Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 239000002077 nanosphere Substances 0.000 claims 2
- 230000004962 physiological condition Effects 0.000 claims 2
- 238000004544 sputter deposition Methods 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 229930186147 Cephalosporin Natural products 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000006968 Helminthiasis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 206010000891 acute myocardial infarction Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- 239000003263 anabolic agent Substances 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000002280 anti-androgenic effect Effects 0.000 claims 1
- 229940046836 anti-estrogen Drugs 0.000 claims 1
- 230000001833 anti-estrogenic effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000003208 anti-thyroid effect Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000000051 antiandrogen Substances 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 229940043671 antithyroid preparations Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000001588 bifunctional effect Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 229940124587 cephalosporin Drugs 0.000 claims 1
- 150000001780 cephalosporins Chemical class 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 239000003667 hormone antagonist Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 239000002858 neurotransmitter agent Substances 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 claims 1
- 229920001432 poly(L-lactide) Polymers 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 239000000583 progesterone congener Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 229960002180 tetracycline Drugs 0.000 claims 1
- 229930101283 tetracycline Natural products 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 239000000083 urinary anti-infective agent Substances 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
- C08G63/08—Lactones or lactides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/66—Polyesters containing oxygen in the form of ether groups
- C08G63/668—Polyesters containing oxygen in the form of ether groups derived from polycarboxylic acids and polyhydroxy compounds
- C08G63/672—Dicarboxylic acids and dihydroxy compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/002—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from unsaturated compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L101/00—Compositions of unspecified macromolecular compounds
- C08L101/16—Compositions of unspecified macromolecular compounds the macromolecular compounds being biodegradable
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L87/00—Compositions of unspecified macromolecular compounds, obtained otherwise than by polymerisation reactions only involving unsaturated carbon-to-carbon bonds
- C08L87/005—Block or graft polymers not provided for in groups C08L1/00 - C08L85/04
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
- C08G2650/38—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type containing oxygen in addition to the ether group
- C08G2650/42—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type containing oxygen in addition to the ether group containing orthoester groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11174987.5 | 2011-07-22 | ||
| EP11174987 | 2011-07-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014102900A Division RU2662818C2 (ru) | 2011-07-22 | 2012-07-23 | Биоразлагаемые полукристаллические термопластичные мультиблочные сополимеры с разделенными фазами для контролируемого высвобождения биологически активных соединений |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018125698A true RU2018125698A (ru) | 2019-03-13 |
Family
ID=46704994
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018125698A RU2018125698A (ru) | 2011-07-22 | 2012-07-23 | Биоразлагаемые полукристаллические термопластичные мультиблочные сополимеры с разделенными фазами для контролируемого высвобождения биологически активных соединений |
| RU2014102900A RU2662818C2 (ru) | 2011-07-22 | 2012-07-23 | Биоразлагаемые полукристаллические термопластичные мультиблочные сополимеры с разделенными фазами для контролируемого высвобождения биологически активных соединений |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014102900A RU2662818C2 (ru) | 2011-07-22 | 2012-07-23 | Биоразлагаемые полукристаллические термопластичные мультиблочные сополимеры с разделенными фазами для контролируемого высвобождения биологически активных соединений |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20140199385A1 (https=) |
| EP (1) | EP2734573B1 (https=) |
| JP (2) | JP6174023B2 (https=) |
| KR (1) | KR101889586B1 (https=) |
| CN (1) | CN103827177B (https=) |
| AU (1) | AU2012287577B2 (https=) |
| BR (1) | BR112014001441A2 (https=) |
| CA (1) | CA2842514C (https=) |
| CL (1) | CL2014000159A1 (https=) |
| CO (1) | CO7020923A2 (https=) |
| ES (1) | ES2899701T3 (https=) |
| IL (1) | IL230606B (https=) |
| MX (1) | MX362941B (https=) |
| MY (1) | MY169349A (https=) |
| PH (1) | PH12014500192A1 (https=) |
| RU (2) | RU2018125698A (https=) |
| UA (1) | UA112192C2 (https=) |
| WO (1) | WO2013015685A1 (https=) |
| ZA (1) | ZA201400846B (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2018125698A (ru) * | 2011-07-22 | 2019-03-13 | Иннокор Текнолоджис Б.В. | Биоразлагаемые полукристаллические термопластичные мультиблочные сополимеры с разделенными фазами для контролируемого высвобождения биологически активных соединений |
| RU2694901C2 (ru) * | 2013-04-18 | 2019-07-18 | Шаньдун Луе Фармасьютикал Ко., Лтд | Фармацевтические композиции микросфер гозерелина с пролонгированным высвобождением |
| JO3394B1 (ar) | 2014-07-04 | 2019-10-20 | Osteo Pharma B V | تركيبات ومنتجات للاستعمال في علاج كسور وعيوب العظام |
| CN105273153A (zh) * | 2014-07-24 | 2016-01-27 | 允友成(宿迁)复合新材料有限公司 | 一种可降解生物基水性乳液及其制备方法 |
| CN105273154A (zh) * | 2014-07-24 | 2016-01-27 | 允友成(宿迁)复合新材料有限公司 | 一种可降解聚乳酸基水性乳液及其制备方法 |
| JP6910949B2 (ja) * | 2014-08-14 | 2021-07-28 | ブラウン ユニバーシティ | タンパク質を安定化させ、送達するための組成物 |
| EP3218022A1 (en) | 2014-11-14 | 2017-09-20 | University College Cork, National University Of Ireland | Delivery of igf-1 in myocardial infarction |
| KR102009972B1 (ko) * | 2015-11-25 | 2019-10-21 | 주식회사 엘지화학 | 양친성 고분자 |
| KR102001614B1 (ko) * | 2015-11-25 | 2019-07-18 | 주식회사 엘지화학 | 양친성 고분자 |
| JP7665280B2 (ja) | 2015-12-22 | 2025-04-21 | アクセス・バスキュラー・インコーポレイテッド | 高強度生体材 |
| CN105461884B (zh) * | 2015-12-22 | 2018-05-29 | 佛山市顺德区福利来酒店傢具有限公司 | 儿童抗菌耐划伤家具及其制备方法 |
| KR101913146B1 (ko) * | 2016-06-16 | 2018-11-01 | 주식회사 엘지화학 | 양친성 트리블록 고분자 |
| WO2017217813A1 (ko) * | 2016-06-16 | 2017-12-21 | 주식회사 엘지화학 | 양친성 고분자 |
| CN109312035B (zh) * | 2016-06-16 | 2021-07-30 | 株式会社Lg化学 | 两亲性聚合物 |
| MX391306B (es) | 2017-01-31 | 2025-03-21 | Veru Inc | COMPOSICIONES PARA LA LIBERACIÓN PROLONGADA DE ANTAGONISTAS DE LA HORMONA LIBERADORA DE GONADOTROPINA (GnRH) |
| CN109876191B (zh) * | 2017-07-15 | 2020-04-03 | 深圳市立心科学有限公司 | 可吸收的生物医用复合材料及其制备方法 |
| CN111372970A (zh) | 2017-10-04 | 2020-07-03 | 时尚化学品股份有限公司 | 新的聚乳酸酯及其组合物 |
| WO2019187569A1 (ja) * | 2018-03-30 | 2019-10-03 | 東レ株式会社 | 生分解性を有するブロック共重合体 |
| CN108387664B (zh) * | 2018-07-03 | 2020-06-23 | 中国食品药品检定研究院 | 人血白蛋白分子大小分布超高效液相色谱测定方法 |
| WO2020071912A1 (en) | 2018-10-02 | 2020-04-09 | Innocore Technologies B.V. | Extended release formulations of human chorionic gonadotropin (hcg) |
| MY203238A (en) | 2018-10-29 | 2024-06-19 | Fraunhofer Ges Zur Frderung Der Angewandten Forschung E V | Tetracycline complexes with sustained activity |
| JP2022514368A (ja) * | 2018-12-19 | 2022-02-10 | アクセス・バスキュラー・インコーポレイテッド | 放出制御用高強度多孔質材料 |
| EA202192644A1 (ru) * | 2019-03-28 | 2021-12-14 | Пк Мед | Многокомпонентный термопластичный продукт |
| US20210017329A1 (en) * | 2019-07-19 | 2021-01-21 | Evonik Operations Gmbh | Multi-block shape memory bioresorbable polymers |
| CA3156256A1 (en) * | 2019-10-01 | 2021-04-08 | InnoCore Technologies Holding B.V. | Biodegradable, phase separated, thermoplastic multi-block copolymer |
| WO2021067388A1 (en) | 2019-10-01 | 2021-04-08 | Allergan Sales, Llc | Poly-dioxanone multi-block copolymer for ocular protein delivery |
| US11819576B2 (en) * | 2019-10-31 | 2023-11-21 | Evonik Operations Gmbh | Process for preparing nano-or microparticles comprising a carrier-polymer and one or more biologically active ingredients |
| US20220409730A1 (en) * | 2019-11-01 | 2022-12-29 | InnoCore Technologies Holding B.V. | Dosage form for extended release of an antibody or large protein |
| US20230055790A1 (en) * | 2019-12-12 | 2023-02-23 | Massachusetts Eye And Ear Infirmary | Melt-extrudable 3d printing inks |
| WO2021168170A1 (en) * | 2020-02-21 | 2021-08-26 | Natureworks Llc | Cosmetic compositions containing low molecular weight amorphous grade polylactic acid resin |
| CN115605248A (zh) | 2020-03-06 | 2023-01-13 | 阿塞斯血管有限公司（Us） | 用于水合制品的包装和相关方法 |
| JP2023522134A (ja) * | 2020-04-10 | 2023-05-26 | サイエンチュア， インコーポレイテッド | 長時間作用型アポモルフィン製剤、およびその治療送達用のインジェクター |
| US20240033221A1 (en) | 2020-04-22 | 2024-02-01 | Scienture, Inc. | Long-acting bupivacaine microsphere formulations |
| CN111484635B (zh) * | 2020-06-10 | 2023-09-12 | 杭州铭善生物科技有限公司 | 一种温敏性水凝胶材料的改性方法、改性温敏性水凝胶材料和生物3d打印墨水 |
| CN112336689B (zh) * | 2020-10-30 | 2022-06-28 | 浙江大学衢州研究院 | 一种结晶性嵌段共聚物胶束制备多重Pickering乳液的方法 |
| US20240082167A1 (en) * | 2021-01-22 | 2024-03-14 | University Of Connecticut | Synthetic artificial stem cells (sasc) |
| US12186722B2 (en) | 2022-02-07 | 2025-01-07 | Honeywell Federal Manufacturing & Technologies, Llc | Porous polysiloxane microspheres |
| CN114737276B (zh) * | 2022-03-11 | 2023-02-07 | 北京朗净汇明生物科技有限公司 | 一种耐热抗水解型聚乳酸纤维及其制备方法 |
| AU2023235001A1 (en) | 2022-03-17 | 2024-10-17 | InnoCore Technologies Holding B.V. | Biodegradable thermoplastic poly(ortho ester) based multiblock copolymers |
| WO2026015019A1 (en) | 2024-07-08 | 2026-01-15 | InnoCore Technologies Holding B.V. | Biodegradable thermoplastic polyoxazoline based copolymers |
| US12514756B1 (en) | 2024-10-08 | 2026-01-06 | Covidien Lp | Dermal patch and systems, kits, and methods associated therewith |
| DE102024129442A1 (de) | 2024-10-11 | 2026-04-16 | Universität Potsdam, Körperschaft des öffentlichen Rechts | Polymer-gekoppelte antikörper und antikörperfragmente |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4429080A (en) | 1982-07-01 | 1984-01-31 | American Cyanamid Company | Synthetic copolymer surgical articles and method of manufacturing the same |
| US5066772A (en) | 1987-12-17 | 1991-11-19 | Allied-Signal Inc. | Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides |
| US5133739A (en) | 1990-02-06 | 1992-07-28 | Ethicon, Inc. | Segmented copolymers of ε-caprolactone and glycolide |
| CN1037612C (zh) * | 1992-07-20 | 1998-03-04 | 中国科学院化学研究所 | 热致形状可回复性多嵌段聚合物材料 |
| US5236444A (en) | 1992-10-27 | 1993-08-17 | United States Surgical Corporation | Absorbable polymers and surgical articles made therefrom |
| NZ261250A (en) * | 1993-01-06 | 1997-08-22 | Kinerton Ltd | Ionic conjugates of polypeptides |
| US5403347A (en) | 1993-05-27 | 1995-04-04 | United States Surgical Corporation | Absorbable block copolymers and surgical articles fabricated therefrom |
| US5711958A (en) | 1996-07-11 | 1998-01-27 | Life Medical Sciences, Inc. | Methods for reducing or eliminating post-surgical adhesion formation |
| US5980948A (en) | 1996-08-16 | 1999-11-09 | Osteotech, Inc. | Polyetherester copolymers as drug delivery matrices |
| US6211249B1 (en) | 1997-07-11 | 2001-04-03 | Life Medical Sciences, Inc. | Polyester polyether block copolymers |
| US6160084A (en) | 1998-02-23 | 2000-12-12 | Massachusetts Institute Of Technology | Biodegradable shape memory polymers |
| US8158143B2 (en) | 2000-07-14 | 2012-04-17 | Helmholtz-Zentrum Geesthacht Zentrum Fuer Material- Und Kuestenforschung Gmbh | Systems for releasing active ingredients, based on biodegradable or biocompatible polymers with a shape memory effect |
| EP1382628A1 (en) * | 2002-07-16 | 2004-01-21 | Polyganics B.V. | Biodegradable phase separated segmented/block co-polyesters |
| EP1555278A1 (en) * | 2004-01-15 | 2005-07-20 | Innocore Technologies B.V. | Biodegradable multi-block co-polymers |
| US20090004243A1 (en) * | 2007-06-29 | 2009-01-01 | Pacetti Stephen D | Biodegradable triblock copolymers for implantable devices |
| RU2018125698A (ru) * | 2011-07-22 | 2019-03-13 | Иннокор Текнолоджис Б.В. | Биоразлагаемые полукристаллические термопластичные мультиблочные сополимеры с разделенными фазами для контролируемого высвобождения биологически активных соединений |
-
2012
- 2012-07-23 RU RU2018125698A patent/RU2018125698A/ru not_active Application Discontinuation
- 2012-07-23 BR BR112014001441A patent/BR112014001441A2/pt not_active Application Discontinuation
- 2012-07-23 CN CN201280040941.7A patent/CN103827177B/zh active Active
- 2012-07-23 US US14/233,961 patent/US20140199385A1/en not_active Abandoned
- 2012-07-23 WO PCT/NL2012/050529 patent/WO2013015685A1/en not_active Ceased
- 2012-07-23 PH PH1/2014/500192A patent/PH12014500192A1/en unknown
- 2012-07-23 MX MX2014000891A patent/MX362941B/es active IP Right Grant
- 2012-07-23 AU AU2012287577A patent/AU2012287577B2/en active Active
- 2012-07-23 EP EP12748568.8A patent/EP2734573B1/en active Active
- 2012-07-23 RU RU2014102900A patent/RU2662818C2/ru active
- 2012-07-23 UA UAA201401832A patent/UA112192C2/uk unknown
- 2012-07-23 ES ES12748568T patent/ES2899701T3/es active Active
- 2012-07-23 MY MYPI2014700136A patent/MY169349A/en unknown
- 2012-07-23 CA CA2842514A patent/CA2842514C/en active Active
- 2012-07-23 KR KR1020147004468A patent/KR101889586B1/ko not_active Expired - Fee Related
- 2012-07-23 JP JP2014521586A patent/JP6174023B2/ja active Active
-
2014
- 2014-01-21 CL CL2014000159A patent/CL2014000159A1/es unknown
- 2014-01-22 IL IL230606A patent/IL230606B/en active IP Right Grant
- 2014-01-23 CO CO14012995A patent/CO7020923A2/es unknown
- 2014-02-04 ZA ZA2014/00846A patent/ZA201400846B/en unknown
-
2017
- 2017-05-16 JP JP2017097345A patent/JP6472836B2/ja active Active
- 2017-08-15 US US15/677,442 patent/US10300019B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MY169349A (en) | 2019-03-21 |
| BR112014001441A2 (pt) | 2019-05-14 |
| UA112192C2 (uk) | 2016-08-10 |
| ZA201400846B (en) | 2016-08-31 |
| PH12014500192A1 (en) | 2014-03-24 |
| JP2017141477A (ja) | 2017-08-17 |
| ES2899701T3 (es) | 2022-03-14 |
| CN103827177A (zh) | 2014-05-28 |
| MX362941B (es) | 2019-02-27 |
| US20180085318A1 (en) | 2018-03-29 |
| US10300019B2 (en) | 2019-05-28 |
| JP6174023B2 (ja) | 2017-08-02 |
| JP6472836B2 (ja) | 2019-02-20 |
| AU2012287577B2 (en) | 2017-02-16 |
| IL230606A0 (en) | 2014-03-31 |
| NZ620392A (en) | 2016-02-26 |
| CN103827177B (zh) | 2016-02-10 |
| EP2734573A1 (en) | 2014-05-28 |
| EP2734573B1 (en) | 2021-09-08 |
| CA2842514C (en) | 2018-12-18 |
| CA2842514A1 (en) | 2013-01-31 |
| CL2014000159A1 (es) | 2014-08-29 |
| US20140199385A1 (en) | 2014-07-17 |
| RU2014102900A (ru) | 2015-08-27 |
| AU2012287577A1 (en) | 2014-03-13 |
| RU2662818C2 (ru) | 2018-07-31 |
| CO7020923A2 (es) | 2014-08-11 |
| KR101889586B1 (ko) | 2018-09-20 |
| IL230606B (en) | 2019-07-31 |
| MX2014000891A (es) | 2015-05-11 |
| KR20140048296A (ko) | 2014-04-23 |
| JP2014521762A (ja) | 2014-08-28 |
| WO2013015685A1 (en) | 2013-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018125698A (ru) | Биоразлагаемые полукристаллические термопластичные мультиблочные сополимеры с разделенными фазами для контролируемого высвобождения биологически активных соединений | |
| JP2017141477A5 (https=) | ||
| Shahriar et al. | Electrospinning nanofibers for therapeutics delivery | |
| Dutta et al. | In situ forming injectable thermoresponsive hydrogels for controlled delivery of biomacromolecules | |
| Domb et al. | Biodegradable polymers in clinical use and clinical development | |
| EP2229150B1 (en) | Systems and methods for delivery of materials | |
| JP3955759B2 (ja) | 有機溶媒に溶解可能なポリ（アルキレンオキサイド）及びポリ（ｐ−ジオキサノン）の生分解性ブロック共重合体及びこれを含有するドラッグデリバリー組成物 | |
| US9364544B2 (en) | Pharmaceutical compositions containing functionalized triblock copolymers | |
| Martins et al. | Preparation and characterization of paclitaxel-loaded PLDLA microspheres | |
| US20090263346A1 (en) | Systems and methods for delivery of drugs | |
| JP6438406B2 (ja) | 疎水性生理活性物質を送達するための組成物および方法 | |
| CN101756908A (zh) | 聚酯包衣的羟基磷灰石微球及其制备方法 | |
| CN101467959A (zh) | 持续释放组合物及其制备方法 | |
| JP6333244B2 (ja) | ポリマー−ｎｓａｉｄコンジュゲート | |
| CN104918638A (zh) | 用于持续递送抗癌剂的丝储库 | |
| KR20080076099A (ko) | 온도 및 피에치 민감성 블록공중합체 고분자 하이드로겔을이용한 주사가능한 약물전달체 및 약물전달방법 | |
| CN102188756A (zh) | 一种含药缓释降解骨支架的制备方法 | |
| Ding et al. | Synthesis and characterization of bovine serum albumin-loaded microspheres based on star-shaped PLLA with a xylitol core and their drug release behaviors | |
| CN103893129B (zh) | 帕潘立酮缓释微球及其注射剂和该缓释微球的制备方法 | |
| Kim et al. | Poly (lactic-co-glycolic acid) microparticles in fibrin glue for local, sustained delivery of bupivacaine | |
| CN102225204A (zh) | 抗肿瘤的pH敏感缓释植入剂及制备方法 | |
| Camargo et al. | Ivermectin-loaded microparticles for parenteral sustained release: in vitro characterization and effect of some formulation variables | |
| CN1939316A (zh) | 含阿霉素的微球,其用途及其制备方法 | |
| CN108815138B (zh) | 利培酮或其衍生物缓释微球、其制备方法及用途 | |
| CN106806899B (zh) | 聚乳酸键载布洛芬缓释前药及其直接熔融共聚制备方法与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20150724 |